Repirinast

• UNSPSC Description:

  Repirinast (MY-5116) is an orally active anti-allergic agent. Repirinast inhibits histamine release. Repirinast can be used in the research of bronchial asthma[1][2][3].

• Target Antigen:

  Histamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/repirinast.html

• Purity:

  95.30

• Solubility:

  DMSO : 5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(C(O1)=CC(C2=C1C3=C(NC2=O)C(C)=C(C)C=C3)=O)OCCC(C)C

• Molecular Weight:

  355.38

• References & Citations:

  [1]N Yamada, et al. Repirinast inhibits antigen-induced early and late pulmonary responses and airway hyperresponsiveness in guinea pigs. Int Arch Allergy Immunol. 1993;100(4):367-72. |[2]Takahashi K. Effects of MY-5116 on experimental asthma in rats and guinea pigs. Arerugi. 1986 Oct; 35(10): 1037-46. |[3]M Takei, et al. Inhibition of histamine release from rat peritoneal mast cells by MY-1250, an active metabolite of Repirinast (MY-5116). Int Arch Allergy Appl Immunol. 1990;93(2-3):237-41.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  73080-51-0